<DOC>
	<DOCNO>NCT01766375</DOCNO>
	<brief_summary>This study multi-center , open , randomized-control study effect safety idarubicin 60mg/M2 combined BUCY pretreatment program BUCY pretreatment program overall survival rate disease-free survival rate acute myeloid leukemia patient high-risk group period 2 year .</brief_summary>
	<brief_title>Effects Safety Idarubicin-strengthened Pretreatment Program Conventional Busulfan Cyclophosphamide Pretreatment Program High-risk Acute Myeloid Leukemia Patient</brief_title>
	<detailed_description>This study multi-center , open , randomized-control study . It evaluate effect safety idarubicin 60mg/M2 combined BUCY pretreatment program BUCY pretreatment program acute myeloid leukemia patient high-risk group . 200 patient study 100 patient group . Patients enrol randomly divide group A ( idarubicin 60mg/M2 combined BUCY group ) group B ( BUCY group ) . SAS randomization software use obtain randomization number . Patients recommend start pretreatment within 7 day randomization . Main objective : 2-year overall survival ( OS ) disease-free survival ( DFS ) rate . Secondary objective : safety evaluation ( early complication transplantation , liver , kidney heart toxicity , treatment-related mortality , blood recovery time ) , median period disease-free survival . Test drug Idarubicin ( Zavedos ® , Pfizer ) , busulfan , cyclophosphamide . Pretreatment plan Drug Group A ( IDA 60mg/M2 + BUCY ) Group B ( BUCY ) IDA : 20mg/m2 day , d-12 ~d-10 , intravenous infusion 1 hour . BU : 4mg/Kg day , oral administration , d-7 ~d-4 , 3.2mg/Kg day , intravenous infusion , d-7~d-4 . CY : 60mg/Kg day , intravenous infusion , d-3~d-2 . GVHD prevention plan GVHD prevent CSA+MMF+MTX sibling allogeneic hematopoietic stem cell transplantation ( start day -1 , 3mg/kg CSA infuse continuous intravenous drip gastrointestinal function return normal method administration change oral administration . 5mg/kg divide twice oral intake , maintain cyclosporine concentration 200-300ug / L ; MTX 15mg/m2 day +1 , 10mg/m2 day +3 , +6 day +11 ( base actual situation day 11 omit ) ; MMF 0.25g BID start day 0 continued month ) . Unrelated allogeneic hematopoietic stem cell transplantation use CSA MMF MTX ATG prevention GVHD . 3mg/kg CSA infuse continuous intravenous drip since day -1 gastrointestinal function return normal administration method change oral . 5mg/kg divide twice oral intake maintain cyclosporine concentration 200-300ug/L ; MTX 15mg/m2 , day +1 , 10mg/m2 day +3 , day +6 day +11 ( base actual situation day 11 omit ) ; MMF 0.5g BID start day 0 continue 3 month ( month later , dose reduce accord hemogram ) ; total ATG 6mg/kg take three day , day -4 day -2 . Relapse intervention Routine preventive DLI recommend , however , tendency recurrence find monitor , chemotherapy , immunotherapy , target therapy , secondary transplantation , etc . use , intervention treatment start time record end time . The efficacy evaluation time point 1 . 1-3 , 6 , 12 , 18 , 24 month transplantation . 2 . Follow-up evaluation : indicator blood routine bone marrow detection , minimal residual disease detection end treatment do regularly .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Age : 18～50 ; 2 . Received peripheral blood hematopoietic stem cell transplantation sibling unrelated allogeneic donor identical match HLA 1 allele mismatch . 3 . Diagnosis : refer 2011 edition AML China Guideline diagnosis treatment diagnosis standard highrisk acute myeloid leukemia develop literature ( see Appendix B ) ; 4 . Under general condition , ECOG score ≤ 1 ; 5 . Normal cardiac function ; 6 . Normal liver renal function : blood bilirubin≤35 μ mol\/L , AST/ALT low twice upper limit normal value , serum creatinine≤ 150 μ mol\/L ; 7 . Subjects sign informed consent form . 1 . Severe uncontrolled infection transplantation ; 2 . With contraindication idarubicin ; 3 . Reached maximum cumulative dose anthracyclines , instance , DNR≥ 450mg/m2 , mitoxantrone≥140mg/m2 , total cumulative dose idarubicin≥ 300mg/m2 ; 4 . The condition meet inclusion criterion . Withdrawal criterion : 1 . Those meet inclusion criterion meet exclusion criterion review ; 2 . Patient withdraws inform consent form ; 3 . Patient violate clinical study protocol ; 4 . Patient experience severe adverse event treatment terminate ; 5 . Patient consider longer fit complete clinical trial researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>idarubicin</keyword>
	<keyword>busulfan</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>pretreatment</keyword>
	<keyword>high-risk acute myeloid leukemia patient</keyword>
</DOC>